As states face a shortening of COVID-19 vaccines, Bharat Biotech’s proposal to establish Bharats Immunologicals and Biologicals Corporation Limited (BIBCOL) new plant in Uttar Pradesh Bulandshahr was approved by the Central Government on Monday (May 12, 2021).
2 crore doses of Covaxin will be produced each month by the new PSU, with BIBCOL being provided with Rs30 crore by the central government.
BIBCOL was founded in Bulandshahar in 1989 in particular and produces vaccines for oral polio and other immunizers.
As a result, some States have suspended vaccination pulls for people aged 18-44 years in India. Vaccines are also rampant in the country. On Wednesday, the government of Delhi led by Arvind Kejriwal said that the under 45s will not receive Covaxin fire on Thursday because of the reserves for the next four days.
Maharashtra too decided to temporarily suspend the vaccination of people between 18 and 44 years of age in relation to jabs deficiency, and to redirect the dosage availability for the age group above 45 years of age.
In the meantime Serum Institute and Bharat Biotech have submitted their production plans to the Center in the following four months and informed the Center that they can ramp up to ten crore doses or 7.8 crore doses by August respectively. The sources stated that for both the companies their production schedule was requested in June, July, August and September by the Union Health ministry and the drug control office of India.
Covaxin and Covishield Oxford-AstraZeneca, produced by the Pune-based Serum Institute of India, are indigenously developed from Hyderabad’s Bharat Biotech and currently are used in India’s coronavirus inoculation drive.
